Mode of Administration: Per oral
Sponsors
Prinston Pharmaceutical Inc, Intas Pharmaceuticals Limited, INTAS PHARMACEUTICALS LIMITED
Conditions
Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lungHealth Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 1: F209- Schizophrenia, unspecified
Unknown Phase
A bioequivalence study of clozapine tablet 100 mg twice daily (test drug) with Clozaril® 100 mg tablets twice daily (reference drug, Novartis pharmaceuticals corporation, USA) in adult schizophrenic patients under fasting conditions.
Active, not recruitingCTRI/2016/07/007065
Target: 38Updated: 2021-11-24
A comparative study of Capecitabine Capsules 500 mg and Capecitabine tablet 500 mg in patients of breast, colon or rectal cancer
Active, not recruitingCTRI/2018/01/011492
Target: 24Updated: 2021-11-24
A STUDY OF CLOZAPINE EXTENDED RELEASE CAPSULE 25 MG WITH CLOZAPINE EXTENDED RELEASE CAPSULE 200 MG IN ADULT SCHIZOPHRENIC PATIENTS UNDER FASTING CONDITIONS.
Active, not recruitingCTRI/2019/10/021798
Target: 82Updated: 2021-11-24
A Study of Clozapine Extended Release Capsule 200 mg Once Daily in Adult Schizophrenic Patients.
Active, not recruitingCTRI/2019/11/022073
Target: 92Updated: 2021-11-24
A study of Etoposide Capsules 100 mg with Vepesid Soft Capsules 100 mg in patients with lung cancer.
Active, not recruitingCTRI/2019/11/022127
Target: 50Updated: 2021-11-24
A Study of Clozapine Extended Release Capsule 200 mg with Clozaril® 100 mg Tablets in Adult Schizophrenic Patients.
Active, not recruitingCTRI/2019/12/022239
Target: 136Updated: 2021-11-24